Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

apatinib 3Taxes 3S 1 (combination) 3Oxaliplatin 3Cisplatin 3sintilimab 2Paclitaxel 2Hyperthermic Intraperitoneal Chemotherapy 2Gastrectomy 2Docetaxel 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1andecaliximab 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Gastric Adenocarcinoma × Oxaliplatin × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06196697 2024-06-27

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Harbin Medical University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡